CD22 and acute lymphoblastic leukemia: Other recent pre-clinical studies support additional genetic modifications to achieve optimal clinical efficacy.66–68 Altogether, there is accumulating evidence pointing to the relevant activity of CD19-CAR T cells and CD22-CAR T cells in R/R ALL.